A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup

JN Justice, L Ferrucci, AB Newman, VR Aroda… - Geroscience, 2018 - Springer
Recent advances indicate that biological aging is a potentially modifiable driver of late-life
function and chronic disease and have led to the development of geroscience-guided …
被引用次数：261 相关文章
[PDF] uconn.edu

[PDF][PDF] A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup

JN Justice, L Ferrucci, AB Newman, VR Aroda… - 2018 - health.uconn.edu
Recent advances indicate that biological aging is a potentially modifiable driver of late-life
function and chronic disease and have led to the development of geroscience-guided …
[PDF] whi.org

[PDF][PDF] A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup

JN Justice, L Ferrucci, AB Newman, VR Aroda… - 2018 - sp.whi.org
Recent advances indicate that biological aging is a potentially modifiable driver of late-life
function and chronic disease and have led to the development of geroscience-guided …

[引用][C] A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup

JN Justice, L Ferrucci, AB Newman, VR Aroda… - GeroScience, 2018 - cir.nii.ac.jp
A framework for selection of blood-based biomarkers for geroscience-guided clinical trials:
report from the TAME Biomarkers Workgroup | CiNii Research CiNii 国立情報学研究所 学術 …

A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup.

JN Justice, L Ferrucci, AB Newman, VR Aroda… - Geroscience, 2018 - europepmc.org
Recent advances indicate that biological aging is a potentially modifiable driver of late-life
function and chronic disease and have led to the development of geroscience-guided …

A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup

JN Justice, L Ferrucci, AB Newman, VR Aroda… - …, 2018 - search.proquest.com
Recent advances indicate that biological aging is a potentially modifiable driver of late-life
function and chronic disease and have led to the development of geroscience-guided …

A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup

JN Justice, L Ferrucci, AB Newman… - …, 2018 - einstein.elsevierpure.com
Recent advances indicate that biological aging is a potentially modifiable driver of late-life
function and chronic disease and have led to the development of geroscience-guided …
[HTML] nih.gov

[HTML][HTML] A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup

JN Justice, L Ferrucci, AB Newman, VR Aroda… - …, 2018 - ncbi.nlm.nih.gov
Recent advances indicate that biological aging is a potentially modifiable driver of late-life
function and chronic disease and have led to the development of geroscience-guided …
[PDF] mcgill.ca

[PDF][PDF] A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup

JN Justice, L Ferrucci, AB Newman, VR Aroda… - 2018 - mcgill.ca
Recent advances indicate that biological aging is a potentially modifiable driver of late-life
function and chronic disease and have led to the development of geroscience-guided …
[PDF] roninbeam.com

[PDF][PDF] A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup

JN Justice - roninbeam.com
Jamie N. Justice selection criteria to the current literature resulted in a short list of blood-
based biomarkers proposed for TAME: IL-6, TNFα-receptor I or II, CRP, GDF15, insulin …